TISIDB

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytosol. Note=Newly synthesized protein initially accumulates in the Golgi region and traffics to the plasma membrane through the exocytic pathway.
Domain	PF07714 Protein tyrosine kinase PF00017 SH2 domain PF00018 SH3 domain
Function	Non-receptor protein tyrosine kinase that is involved in the regulation of cell growth and survival, apoptosis, cell-cell adhesion, cytoskeleton remodeling, and differentiation. Stimulation by receptor tyrosine kinases (RTKs) including EGRF, PDGFR, CSF1R and FGFR leads to recruitment of YES1 to the phosphorylated receptor, and activation and phosphorylation of downstream substrates. Upon EGFR activation, promotes the phosphorylation of PARD3 to favor epithelial tight junction assembly. Participates in the phosphorylation of specific junctional components such as CTNND1 by stimulating the FYN and FER tyrosine kinases at cell-cell contacts. Upon T-cell stimulation by CXCL12, phosphorylates collapsin response mediator protein 2/DPYSL2 and induces T-cell migration. Participates in CD95L/FASLG signaling pathway and mediates AKT-mediated cell migration. Plays a role in cell cycle progression by phosphorylating the cyclin-dependent kinase 4/CDK4 thus regulating the G1 phase. Also involved in G2/M progression and cytokinesis.

> Gene Ontology [ TOP ]
Biological Process	GO:0001101 response to acid chemical GO:0002429 immune response-activating cell surface receptor signaling pathway GO:0002431 Fc receptor mediated stimulatory signaling pathway GO:0002433 immune response-regulating cell surface receptor signaling pathway involved in phagocytosis GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002757 immune response-activating signal transduction GO:0002764 immune response-regulating signaling pathway GO:0002768 immune response-regulating cell surface receptor signaling pathway GO:0003013 circulatory system process GO:0003018 vascular process in circulatory system GO:0006909 phagocytosis GO:0007159 leukocyte cell-cell adhesion GO:0008015 blood circulation GO:0008643 carbohydrate transport GO:0008645 hexose transport GO:0015749 monosaccharide transport GO:0015758 glucose transport GO:0018108 peptidyl-tyrosine phosphorylation GO:0018212 peptidyl-tyrosine modification GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0031294 lymphocyte costimulation GO:0031295 T cell costimulation GO:0032526 response to retinoic acid GO:0036119 response to platelet-derived growth factor GO:0036120 cellular response to platelet-derived growth factor stimulus GO:0038083 peptidyl-tyrosine autophosphorylation GO:0038093 Fc receptor signaling pathway GO:0038094 Fc-gamma receptor signaling pathway GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0042110 T cell activation GO:0043114 regulation of vascular permeability GO:0045785 positive regulation of cell adhesion GO:0046777 protein autophosphorylation GO:0048013 ephrin receptor signaling pathway GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0050900 leukocyte migration GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071229 cellular response to acid chemical GO:0071300 cellular response to retinoic acid GO:0071396 cellular response to lipid GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0071593 lymphocyte aggregation GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion
Molecular Function	GO:0004713 protein tyrosine kinase activity GO:0004715 non-membrane spanning protein tyrosine kinase activity GO:0005154 epidermal growth factor receptor binding GO:0044325 ion channel binding GO:0070851 growth factor receptor binding
Cellular Component	GO:0005884 actin filament GO:0005924 cell-substrate adherens junction GO:0005925 focal adhesion GO:0009898 cytoplasmic side of plasma membrane GO:0015629 actin cytoskeleton GO:0019897 extrinsic component of plasma membrane GO:0019898 extrinsic component of membrane GO:0030055 cell-substrate junction GO:0031234 extrinsic component of cytoplasmic side of plasma membrane GO:0098552 side of membrane GO:0098562 cytoplasmic side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04520 Adherens junction
Reactome	R-HSA-1280218: Adaptive Immune System R-HSA-422475: Axon guidance R-HSA-389356: CD28 co-stimulation R-HSA-389513: CTLA4 inhibitory signaling R-HSA-202733: Cell surface interactions at the vascular wall R-HSA-388841: Costimulation by the CD28 family R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1266738: Developmental Biology R-HSA-2682334: EPH-Ephrin signaling R-HSA-3928665: EPH-ephrin mediated repulsion of cells R-HSA-3928663: EPHA-mediated growth cone collapse R-HSA-3928662: EPHB-mediated forward signaling R-HSA-2029481: FCGR activation R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis R-HSA-109582: Hemostasis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling R-HSA-210990: PECAM1 interactions R-HSA-1433559: Regulation of KIT signaling R-HSA-912631: Regulation of signaling by CBL R-HSA-162582: Signal Transduction R-HSA-1227986: Signaling by ERBB2 R-HSA-449147: Signaling by Interleukins R-HSA-1433557: Signaling by SCF-KIT

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04520 Adherens junction

Reactome

R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-389356: CD28 co-stimulation
R-HSA-389513: CTLA4 inhibitory signaling
R-HSA-202733: Cell surface interactions at the vascular wall
R-HSA-388841: Costimulation by the CD28 family
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1266738: Developmental Biology
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-3928663: EPHA-mediated growth cone collapse
R-HSA-3928662: EPHB-mediated forward signaling
R-HSA-2029481: FCGR activation
R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis
R-HSA-109582: Hemostasis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-512988: Interleukin-3, 5 and GM-CSF signaling
R-HSA-210990: PECAM1 interactions
R-HSA-1433559: Regulation of KIT signaling
R-HSA-912631: Regulation of signaling by CBL
R-HSA-162582: Signal Transduction
R-HSA-1227986: Signaling by ERBB2
R-HSA-449147: Signaling by Interleukins
R-HSA-1433557: Signaling by SCF-KIT

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between YES1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of YES1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	Total # shRNA with >= 4-fold: 1	Resistant to T-cell proliferation
24476824	shRNA	melanoma	B16	Secondary screen	Total # shRNA with >= 4-fold: 3	Resistant to T-cell proliferation

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of YES1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.274	0.336
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.603	0.737
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.029	0.981
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.044	0.914
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.279	0.875
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.461	0.851
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.005	0.99
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.259	0.882
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.295	0.877
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.152	0.895
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.988	0.553
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.112	0.191

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of YES1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	5.9	3.6	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of YES1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of YES1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by YES1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of YES1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of YES1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between YES1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	YES1
Name	YES proto-oncogene 1, Src family tyrosine kinase
Aliases	Yes; c-yes; HsT441; v-yes-1 Yamaguchi sarcoma viral oncogene homolog 1; P61-YES; YES1 proto-oncogene, Src fa ......
Chromosomal Location	18p11.31-p11.21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting YES1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting YES1.

ID	Name	Drug Type	Targets	#Targets
DB01254	Dasatinib	Small Molecule	ABL1, ABL2, BCR, BTK, CSK, EPHA2, EPHA5, EPHB4, FGR, FRK, FYN, HSP ......	22

Browse YES1